Researchers report that PD - 1 / PD - L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently
preventing tumor resistance.
Not exact matches
The authors said their results, which they have made publicly available, constitute an invaluable resource to help clinicians predict which chemotherapies will be most effective against
tumor cells with particular genetic mutations, and how to rationally combine therapies to
prevent cancers from developing
resistance.
«New study shows promise for
preventing therapy
resistance in
tumor cells.»
However, it may be possible to
prevent resistance and
tumor recurrence by targeting both mitochondrial metabolism and FGFR3 - TACC3 directly.»